$-0.06
(Market cap
$1,515 Mln
Revenue (TTM)
$443 Mln
P/E Ratio
4.9
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.4 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
2.6
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$4
-
Face value
--
-
Shares outstanding
72,245,485
10 Years Aggregate
CFO
$1,582.85 Mln
EBITDA
$1,824.32 Mln
Net Profit
$1,442.70 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Innoviva (INVA)
| 6.5 | 2.5 | -1.9 | 1.9 | 18.4 | 6.7 | 6.7 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Innoviva (INVA)
| 15.2 | 8.1 | 21.1 | -23.2 | 39.2 | -12.5 | -18.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Innoviva (INVA)
|
21.3 | 1,515.0 | 443.4 | 357.2 | 165.4 | 29.7 | 4.9 | 1.2 |
| 17.6 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 207.7 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 74.4 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 110.1 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.5 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 286.5 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.4 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 124.8 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Innoviva (INVA)
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid,... and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Read more
-
Chief Executive Officer
Mr. Pavel Raifeld C.F.A.
-
Chief Executive Officer
Mr. Pavel Raifeld C.F.A.
-
Headquarters
Burlingame, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Innoviva (INVA)
What is the current share price of Innoviva Inc (INVA) Today?
The share price of Innoviva Inc (INVA) is $21.29 (NASDAQ) as of 04-Sep-2026 11:34 EDT. Innoviva Inc (INVA) has given a return of 18.42% in the last 3 years.
What is the current PB & PE ratio of Innoviva Inc (INVA)?
The P/E ratio of Innoviva Inc (INVA) is 4.87 times as on 28-Aug-2026, a 87 discount to its peers’ median range of 37.32 times.
The P/B ratio of Innoviva Inc (INVA) is 1.23 times as on 28-Aug-2026, a 84 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
6.29 |
1.45 |
2024 |
62.45 |
2.11 |
2023 |
7.59 |
2.02 |
2022 |
4.31 |
1.63 |
2021 |
5.31 |
3.40 |
What is the 52 Week High and Low of Innoviva Inc (INVA)?
The 52-week high and low of Innoviva Inc (INVA) are Rs 25.15 and Rs 16.52 as of 04-Sep-2026.
What is the market cap of Innoviva Inc (INVA)?
Innoviva Inc (INVA) has a market capitalisation of $ 1,515 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Innoviva Inc (INVA)?
Before investing in Innoviva Inc (INVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.